Abstracts tagged "Clinical research and psoriatic arthritis"

Abstract Number: 2554 • 2018 ACR/ARHP Annual Meeting
Abatacept without Methotrexate in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of a Phase III, Randomized Study
Vibeke Strand¹, Thomas Lehman², Harris A Ahmad², Alyssa Johnsen², Sandhya Balachandar² and Philip J. Mease³, ¹Stanford University, Palo Alto, CA, ²Bristol-Myers Squibb, Princeton, NJ, ³Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: In the randomized, placebo (pbo)-controlled Phase III ASTRAEA study (ClinicalTrials.gov, NCT01860976) patients (pts) with active psoriatic arthritis (PsA) were randomized to abatacept (ABA) or…
Abstract Number: 1041 • 2016 ACR/ARHP Annual Meeting
Abatacept in the Treatment of Active Psoriatic Arthritis: 24-Week Results from a Phase III Study
P Mease¹, AB Gottlieb², D van der Heijde³, Oliver FitzGerald⁴, A Johnsen⁵, M Nys⁶, S Banerjee⁵ and D Gladman⁷, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Tufts University School of Medicine (affiliation at the time of the study), Boston, MA, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Rheumatology, St Vincent’s University Hospital and University College Dublin, Dublin, Ireland, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Bristol-Myers Squibb, Braine-l’Alleud, Belgium, ⁷Rheumatology, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Abatacept (ABA), a selective T-cell co-stimulation modulator, showed promise for the treatment of PsA in a Phase II trial.1 This prompted the conduct of…
Abstract Number: 1852 • 2014 ACR/ARHP Annual Meeting
Increased Cardiovascular Risk in Patients Recently Diagnosed with Psoriatic Arthritis: A Population-Based, Cohort Study
Katelynn Wilton¹, Floranne C. Ernste², Cynthia S. Crowson³, Eric L. Matteson⁴, Hilal Maradit Kremers⁵ and Marta Sánchez-Menéndez⁶, ¹Medical Scientist Training Program, Mayo Clinic Rochester, Rochester, MN, ²Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Health Sciences Research, Mayo Clinic, Rochester, MN, ⁶Centro Medico de Asturias, Oviedo, Spain
Background/Purpose: Patients diagnosed with rheumatoid arthritis and psoriatic arthritis (PsA) have an increased risk of multiple comorbidities that predispose them to cardiovascular disease (CVD). Although…
Abstract Number: 327 • 2013 ACR/ARHP Annual Meeting
Major Differences In The Pattern Of Joint Swelling and Tenderness In a Large Psoriatic Arthritis Cohort – Results From An Exploratory Hierarchical Cluster Analysis
Burkhard Möller¹, Daniel Stekhoven² and Peter M. Villiger³, ¹Rheumatology, Inselspital, Bern, Switzerland, ²Swiss Clinical Quality Management in Rheumatic Diseases-SCQM Foundation, Zurich, Switzerland, ³Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
Background/Purpose: Psoriatic arthritis (PsA) shows the largest complexity in joint involvement among all inflammatory types of arthritis. In order to improve feasibility and to reduce…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].